|1.||Ford, Ian: 33 articles (12/2015 - 11/2006)|
|2.||Böhm, Michael: 32 articles (12/2015 - 01/2007)|
|3.||Borer, Jeffrey S: 29 articles (12/2015 - 02/2003)|
|4.||Komajda, Michel: 25 articles (12/2015 - 01/2010)|
|5.||Tavazzi, Luigi: 25 articles (12/2015 - 06/2008)|
|6.||Swedberg, Karl: 24 articles (12/2015 - 01/2010)|
|7.||Tardif, Jean-Claude: 16 articles (12/2015 - 01/2007)|
|8.||Ferrari, Roberto: 13 articles (12/2015 - 05/2006)|
|9.||Fox, Kim: 12 articles (12/2015 - 02/2003)|
|10.||Tendera, Michal: 11 articles (12/2015 - 11/2006)|
11/01/2014 - "Cost-effectiveness of ivabradine was assessed by the National Institute for Health and Clinical Excellence (NICE) in 2012, based on the data derived from the SHIFT trial: NICE considered ivabradine cost-effective for treating chronic heart failure, supporting drug reimbursement by the national healthcare system (NHS). "
07/01/2014 - "Ivabradine is cost-effective in the treatment of chronic heart failure."
09/01/2008 - "We also now have another bradycardic agent, ivabradine, which may prove very useful in heart failure patients who cannot tolerate a betablocker."
01/01/2011 - "Aim of the study - to determine efficacy of therapy with the use of ivabradine in patients with functional class (FC) III chronic heart failure (CHF) on the basis of assessment of its action on regulatory adaptive status (RAS). "
04/01/2015 - "[The efficacy of ivabradine in chronic heart failure (review)]."
01/01/2009 - "The results of our study show that patients with inappropriate sinus tachycardia can be successfully treated with ivabradine."
10/09/2012 - "In this cohort, ivabradine significantly improved symptoms associated with inappropriate sinus tachycardia and completely eliminated them in approximately half of the patients. "
12/01/2010 - "Ivabradine appears effective and safe in patients with symptomatic inappropriate sinus tachycardia."
10/09/2012 - "Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation."
09/01/2010 - "Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia."
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
10/01/2009 - "Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease. "
04/01/2013 - "The addition of ivabradine to optimal medical therapy in patients with stable coronary artery disease is associated with significant improvement in anginal symptoms and functional capacity."
12/01/2008 - "Ivabradine failed to reduce the incidence of cardiovascular events in patients with coronary artery disease and left ventricular systolic dysfunction in the BEAUTIFUL study, but patients with higher heart rates might have benefited. "
05/27/2009 - "Ivabradine is a new efficient and safe therapeutic option in the treatment of coronary artery disease. "
01/01/2015 - "The study assessing the morbidity-mortality Benefits of the If Inhibitor, Ivabradine, in patients with coronary artery disease (SIGNIFY) tested this hypothesis. "
11/01/2014 - "Clinical trials have proven the anti-anginal and anti-ischemic efficacy of the pacemaker current inhibitor ivabradine in combination with beta-blockers in patients with stable angina pectoris (AP). "
11/01/2014 - "In daily clinical practice, addition of ivabradine to beta-blockers was effective in reducing HR, angina attacks and nitrate consumption in elderly patients (≥ 75 years) with stable angina pectoris. "
05/01/2012 - "Several clinical trials have demonstrated the antianginal and anti-ischemic efficacy of ivabradine in combination with beta-blocker in patients with stable angina pectoris. "
10/01/2015 - "The addition of ivabradine to the treatment regimen of patients with stable angina pectoris both lowered heart rate and improved endothelial function. "
02/01/2011 - "The REDUCTION multicenter study evaluated the efficacy of ivabradine in stable angina pectoris in everyday practice. "
|5.||Chronic Obstructive Pulmonary Disease (COPD)
12/10/2013 - "Ivabradine is similarly effective and safe in chronic HF patients with or without COPD, and can be safely combined with beta-blockers in COPD."
01/01/2012 - "[Efficacy of ivabradine in patients with stable angina and comorbid chronic obstructive pulmonary disease]."
12/10/2013 - "The primary endpoint (PEP) and its component, hospitalisation for worsening HF, were more frequent in COPD patients (HRs f, 1.22 [p=0.006]; and 1.34 [p<0.001]) respectively, but relative risk was reduced similarly by ivabradine in both COPD (14%, and 17%) and non-COPD (18% and 27%) patients (p interaction=0.82, and 0.53, respectively). "
12/10/2013 - "Multivariate Cox model analyses were performed to compare the COPD (n=730) and non-COPD subgroups, and the ivabradine and placebo treatment effects. "
12/10/2013 - "We investigated clinical profile and outcomes of patients with chronic HF and COPD, notably the efficacy and safety of ivabradine, a heart rate-reducing agent. "
|3.||Mineralocorticoid Receptors (Mineralocorticoid Receptor)
|4.||bipiperidyl mustard (BPM)
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|9.||Angiotensin Receptor Antagonists
|2.||Cardiac Resynchronization Therapy
|5.||Electric Countershock (Cardioversion)